Results 121 to 130 of about 485 (159)

Headache service quality in Egypt: current status, identified gaps, and strategic directions. [PDF]

Front Neurol
Hassan A, Hussein M, Magdy R, Uludüz D, Özge A, Taşdelen S, Amirguliyev S, Şaşmaz T, Abdulghani MO, Moustafa RR, Essmat A, Yacoub O, Abdelghaffar M, Taha NA, Elgenidi A, Merghany N, Farag SM, Fayez MM, Khalil DM, Burstein R.   +19 more
europepmc   +1 more source

Assessment of Chocolate, Cheese, and Caffeine as Migraine Triggers: A Systematic Review and Meta-Analysis of Patient-Reported Trigger Rates. [PDF]

J Nutr Metab
Alzahrani H.
europepmc   +1 more source

Abstracts of Fourth Ditan International Conference on Infectious Diseases - Changing Face of Infectious Diseases. 15-18 July 2010, Beijing.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2010
openaire   +1 more source

RETRACTED: Middle meningeal artery embolization in migraine: From concept to reality.

Interv Neuroradiol
Mortezaei A, Essibayi MA, Osama M, Abdollahifard S, Karandish A, Terraciano A, Fortunel A, Altschul DJ.   +7 more
europepmc   +1 more source

CGRP 関連抗体薬やDitan 系の若年者へのニーズと効果

Japanese Journal of Headache
openaire   +1 more source

The 5-HT1F Receptor as the Target of Ditans in Migraine — From Bench to Bedside

Nature Reviews Neurology, 2023
Migraine is a leading cause of disability in more than one billion people worldwide, yet it remains universally underappreciated, even by individuals with the condition. Among other shortcomings, current treatments (often repurposed agents) have limited efficacy and potential adverse effects, leading to low treatment adherence.
Christian Waeber, Antoinette MaassenVanDenBrink, Margarita Sánchez-Del-Río   +2 more
exaly   +9 more sources

Ditans: A New Prospective for the Therapy of Migraine Attack?

Neurological Sciences, 2022
Migraine attack is characterized by disabling pain and associated symptoms. Triptans represent the "gold standard" therapy, but cardiac subjects have significant limitations for this approach. New drug families are under consideration to expand therapeutic offerings, especially in the presence of contraindications or for non-responsive patients.
Giovanna Viticchi, Lorenzo Falsetti, Mauro Silvestrini   +2 more
exaly   +4 more sources

Drug Interactions and Risks Associated With the Use of Triptans, Ditans and Monoclonal Antibodies in Migraine

Current Opinion in Neurology, 2021
Purpose of review The aim of this study was to review current evidence concerning potential risks and interactions associated with concomitant use of drugs indicated for the abortive treatment of migraine, namely triptans and ditans, and more recently developed drugs used for the preventive treatment.
Antoinette MaassenVanDenBrink
exaly   +4 more sources

CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine

Journal of Clinical Medicine, 2021
Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment.
Luana Lionetto, Paolo Martelletti
exaly   +2 more sources